Filing Details
- Accession Number:
- 0001209191-17-052039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-08 16:11:19
- Reporting Period:
- 2017-09-06
- Accepted Time:
- 2017-09-08 16:11:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1401667 | Puma Biotechnology Inc. | PBYI | Pharmaceutical Preparations (2834) | 770683487 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1553037 | Paul Richard Bryce | C/O Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles CA 90024 | Sr Vp, Clinical Research & Dev | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-09-06 | 1,000 | $11.30 | 28,239 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-09-06 | 1,000 | $100.00 | 27,239 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-09-07 | 14,000 | $11.30 | 41,239 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-09-07 | 14,000 | $100.10 | 27,239 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | STOCK OPTION (RIGHT TO BUY) | Disposition | 2017-09-06 | 1,000 | $0.00 | 1,000 | $11.30 |
| Common Stock | STOCK OPTION (RIGHT TO BUY) | Disposition | 2017-09-07 | 14,000 | $0.00 | 14,000 | $11.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 96,000 | 2022-06-26 | No | 4 | M | Direct | |
| 82,000 | 2022-06-26 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The option is fully vested and is exercisable.
Billionaire Hedge Funds
